Plasma high density lipoproteins and lipolytic enzyme activities in diabetic patients
(1983) In Acta Medica Scandinavica 213(2). p.123-128- Abstract
- Eighty diabetic patients, consecutively selected from an out-patient clinic, were studied with regard to plasma lipoprotein levels, especially HDL. Patients treated with sulphonylureas had 24% lower HDL cholesterol concentrations (p less than 0.01) but only about 7% lower apo AI levels (n.s.) than those on insulin treatment. This difference could at least partly be explained by differences in age and type of diabetes. There was no relationship between the degree of diabetic control, as measured by fasting blood glucose levels, and HDL levels. In two subgroups of insulin-treated diabetics, selected to represent extremely low and high HDL levels (range 0.5-0.8 and 1.8-2.0 mmol/l, respectively) but matched with regard to age, duration of... (More)
- Eighty diabetic patients, consecutively selected from an out-patient clinic, were studied with regard to plasma lipoprotein levels, especially HDL. Patients treated with sulphonylureas had 24% lower HDL cholesterol concentrations (p less than 0.01) but only about 7% lower apo AI levels (n.s.) than those on insulin treatment. This difference could at least partly be explained by differences in age and type of diabetes. There was no relationship between the degree of diabetic control, as measured by fasting blood glucose levels, and HDL levels. In two subgroups of insulin-treated diabetics, selected to represent extremely low and high HDL levels (range 0.5-0.8 and 1.8-2.0 mmol/l, respectively) but matched with regard to age, duration of diabetes, insulin dosage and diabetic control, the activities of lipoprotein lipase and hepatic lipase in postheparin plasma were also recorded. The high HDL group had significantly higher lipoprotein lipase activities (p less than 0.01) and significantly lower hepatic lipase activities (p less than 0.05) than the low HDL group, supporting the hypothetical roles of these enzymes in HDL metabolism, and offering a tentative mechanism behind the large variability of HDL levels in diabetics. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1103131
- author
- Agardh, Carl-David LU ; Sartor, G and Nilsson-Ehle, Peter LU
- organization
- publishing date
- 1983
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Medica Scandinavica
- volume
- 213
- issue
- 2
- pages
- 123 - 128
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:6340423
- scopus:0020662569
- ISSN
- 0001-6101
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Unit on Vascular Diabetic Complications (013241510), Division of Clinical Chemistry and Pharmacology (013250300)
- id
- 35634ebc-3c61-4be1-a89e-7092bb65f81d (old id 1103131)
- date added to LUP
- 2016-04-01 17:04:57
- date last changed
- 2021-01-03 11:34:04
@article{35634ebc-3c61-4be1-a89e-7092bb65f81d, abstract = {{Eighty diabetic patients, consecutively selected from an out-patient clinic, were studied with regard to plasma lipoprotein levels, especially HDL. Patients treated with sulphonylureas had 24% lower HDL cholesterol concentrations (p less than 0.01) but only about 7% lower apo AI levels (n.s.) than those on insulin treatment. This difference could at least partly be explained by differences in age and type of diabetes. There was no relationship between the degree of diabetic control, as measured by fasting blood glucose levels, and HDL levels. In two subgroups of insulin-treated diabetics, selected to represent extremely low and high HDL levels (range 0.5-0.8 and 1.8-2.0 mmol/l, respectively) but matched with regard to age, duration of diabetes, insulin dosage and diabetic control, the activities of lipoprotein lipase and hepatic lipase in postheparin plasma were also recorded. The high HDL group had significantly higher lipoprotein lipase activities (p less than 0.01) and significantly lower hepatic lipase activities (p less than 0.05) than the low HDL group, supporting the hypothetical roles of these enzymes in HDL metabolism, and offering a tentative mechanism behind the large variability of HDL levels in diabetics.}}, author = {{Agardh, Carl-David and Sartor, G and Nilsson-Ehle, Peter}}, issn = {{0001-6101}}, language = {{eng}}, number = {{2}}, pages = {{123--128}}, publisher = {{Wiley-Blackwell}}, series = {{Acta Medica Scandinavica}}, title = {{Plasma high density lipoproteins and lipolytic enzyme activities in diabetic patients}}, volume = {{213}}, year = {{1983}}, }